Skip to main content

Advertisement

SpringerLink
Log in

Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

The vasoactive intestinal peptide receptor-1(VIPR1) has prominent growth effects on a number of common neoplasms. However, there were contradictions in the effect cross different cancers. We aimed to explore the effect of VIPR1 overexpression on a human lung adenocarcinoma cell line H1299. GEO dataset was used to screen differentially expressed genes in lung adenocarcinoma tissues. The expression of VIPR1 mRNA was determined in the cancer Genome Atlas (TCGA). Immunohistochemical analysis was performed to determine VIPR1 protein expression in lung adenocarcinoma and corresponding adjacent tissues (n = 22). Fluorescence real-time quantitative PCR detected the expression of VIPR1 in human normal lung epithelial cell line BEAS-2B and lung adenocarcinoma cell line H1299. Overexpression strategies were employed to assess functions of VIPR1 expression on several malignant phenotypes in H1299. The expression of VIPR1 was lower in lung adenocarcinoma tissues than that in adjacent tissues. Compared with the normal lung epithelial cells BEAS-2B, VIPR1 was down-regulated in lung cancer cells H1299 (P < 0.05). After the overexpression of VIPR1, we found that VIPR1 significantly inhibited growth, migration, and invasion of H1299 cells (P < 0.05). Our findings point out the tumor suppressor roles of VIPR1 in human LUAD pathogenesis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.

    Article  PubMed  Google Scholar 

  2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–94. https://doi.org/10.4065/83.5.584.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Szilasi M, Buglyo A, Treszl A, Kiss L, Schally AV, Halmos G. Gene expression of vasoactive intestinal peptide receptors in human lung cancer. Int J Oncol. 2011;39(4):1019–24. https://doi.org/10.3892/ijo.2011.1122.

    Article  CAS  PubMed  Google Scholar 

  4. Zhu LX, Li CY, Shi QY, Ji CF. Effect of iontophoretic 5-HT on raphe-spinal neurons. Acta Pharmacol Sin. 1986;7(5):394–8.

    CAS  Google Scholar 

  5. Li JM, Darlak KA, Southerland L, Hossain MS, Jaye DL, Josephson CD, Rosenthal H, Waller EK. VIPhyb, an antagonist of vasoactive intestinal peptide receptor, enhances cellular antiviral immunity in murine cytomegalovirus infected mice. PLoS ONE. 2013;8(5):e63381. https://doi.org/10.1371/journal.pone.0063381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Moody TW, Dudek J, Zakowicz H, Walters J, Jensen RT, Petricoin E, Couldrey C, Green JE. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice. Life Sci. 2004;74(11):1345–57. https://doi.org/10.1016/j.lfs.2003.07.043.

    Article  CAS  PubMed  Google Scholar 

  7. Moody TW, Leyton J, Chan D, Brenneman DC, Fridkin M, Gelber E, Levy A, Gozes I. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells. Breast Cancer Res Treat. 2001;68(1):55–64.

    Article  CAS  Google Scholar 

  8. Yassin MA, Datiko DG, Tulloch O, Markos P, Aschalew M, Shargie EB, Dangisso MH, Komatsu R, Sahu S, Blok L, Cuevas LE, Theobald S. Innovative community-based approaches doubled tuberculosis case notification and improve treatment outcome in Southern Ethiopia. PLoS ONE. 2013;8(5):e63174. https://doi.org/10.1371/journal.pone.0063174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer. Curr Opin Endocrinol Diabetes Obes. 2016;23(1):38–47. https://doi.org/10.1097/med.0000000000000218.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Moody TW, Osefo N, Nuche-Berenguer B, Ridnour L, Wink D, Jensen RT. Pituitary adenylate cyclase-activating polypeptide causes tyrosine phosphorylation of the epidermal growth factor receptor in lung cancer cells. J Pharmacol Exp Ther. 2012;341(3):873–81. https://doi.org/10.1124/jpet.111.190033.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Moody TW, Zia F, Draoui M, Brenneman DE, Fridkin M, Davidson A, Gozes I. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth. Proc Natl Acad Sci USA. 1993;90(10):4345–9. https://doi.org/10.1073/pnas.90.10.4345.

    Article  CAS  PubMed  Google Scholar 

  12. Collado B, Carmena MJ, Sanchez-Chapado M, Ruiz-Villaespesa A, Bajo AM, Fernandez-Martinez AB, Varga JL, Schally AV, Prieto JC. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog. Int J Oncol. 2005;26(6):1629–35. https://doi.org/10.3892/ijo.26.6.1629.

    Article  CAS  PubMed  Google Scholar 

  13. Goursaud S, Pineau N, Becq-Giraudon L, Gressens P, Muller JM, Janet T. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor. J Neuroimmunol. 2005;158(1–2):94–105. https://doi.org/10.1016/j.jneuroim.2004.08.018.

    Article  CAS  PubMed  Google Scholar 

  14. Fruhwald MC, O’Dorisio MS, Fleitz J, Pietsch T, Reubi JC. Vasoactive intestinal peptide (VIP) and VIP receptors: gene expression and growth modulation in medulloblastoma and other central primitive neuroectodermal tumors of childhood. Int J Cancer. 1999;81(2):165–73.

    Article  CAS  Google Scholar 

  15. Liu S, Zeng Y, Li Y, Guo W, Liu J, Ouyang N. VPAC1 overexpression is associated with poor differentiation in colon cancer. Tumour Biol. 2014;35(7):6397–404. https://doi.org/10.1007/s13277-014-1852-x.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Second Affiliated Hospital, Zhejiang University School of Medicine, 88 Jiefang Road, Shangcheng District, Hangzhou, 310009, China

    Lufeng Zhao, Zipu Yu & Baiqin Zhao

Authors
  1. Lufeng Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zipu Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Baiqin Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baiqin Zhao.

Ethics declarations

Conflict of interest

We have no conflicts of interest to declare.

Ethical approval

The experimental protocol was established, according to the ethical guidelines of the Helsinki Declaration and was approved by the Human Ethics Committee of Second Affiliated Hospital, Zhejiang University School of Medicine.

Informed consent

Written informed consent was obtained from individual or guardian participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, L., Yu, Z. & Zhao, B. Mechanism of VIPR1 gene regulating human lung adenocarcinoma H1299 cells. Med Oncol 36, 91 (2019). https://doi.org/10.1007/s12032-019-1312-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12032-019-1312-y

Keywords

Search

Navigation